Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology.
about
Rivastigmine for Alzheimer's diseaseRivastigmine for Alzheimer's diseaseCholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's diseaseRivastigmine for Alzheimer's diseaseMulti-Target Directed Donepezil-Like Ligands for Alzheimer's DiseaseDifferent cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.A novel effect of rivastigmine on pre-synaptic proteins and neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in Alzheimer's diseaseProgression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment.The spectrum of cognitive impairment in Lewy body diseasesUPDATE ON DEMENTIA WITH LEWY BODIES.Conceptual and methodological issues in designing a randomized, controlled treatment trial for geriatric bipolar disorder: GERI-BDDonepezil in Alzheimer's disease: From conventional trials to pharmacogeneticsCholinesterase inhibitors in Alzheimer's disease and Lewy body spectrum disorders: the emerging pharmacogenetic story.Donepezil: an update.Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.Distinguishing Lewy body dementias from Alzheimer's disease.Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid-β peptide in mice.Dementia With Lew Body: Impacts of Surgery.Cholinesterase Inhibitory Activities of Adamantyl-Based Derivatives and Their Molecular Docking Studies.
P2860
Q24186551-CA86EF62-A294-4F58-9BDB-5B673058342CQ24187067-A202C9E7-E4E5-4D3D-BC16-D4070108C528Q24201307-6DF2D706-9C11-4BFA-97B6-FB5FEE9B54F3Q24241686-56A0CD93-D755-4A24-B019-061012E58867Q26744105-F1FCC9AA-055D-4F20-80F7-95028C68E282Q33715239-B4A6B02B-56F7-4EB3-8DBA-585F88755906Q33896054-E5FAEBB0-714E-4C24-AE30-B6281A66644DQ33968308-3CCACB79-EC6E-411D-9BF4-AC7A080D75D7Q34019751-3ADE5AC2-B7E0-45BA-B814-5A5149E2BDA1Q34450376-B7333015-8231-4EEE-8442-46DD32825177Q34575982-D29B8054-D7F8-40B5-B17A-EEA9E1DC40ECQ34965949-A44F62C7-9535-404E-A82B-9B2F28F56D7EQ36475090-FAFF9275-BE24-4839-B438-031623C87DE9Q36808057-030692BE-E21A-4881-A47E-231F8A83A314Q36897422-B6329D0A-BBAA-4150-836E-4AC3DBA349B2Q36998833-B42D86DD-5A52-4BAE-9639-678F53D38150Q37163288-D94673F1-CB10-46A7-B156-3FC4074BED94Q38501488-1184836A-949A-4120-8F98-E23142E34AF8Q48005010-4B241AFF-A7E5-4D3F-82C9-CFEDE48D3613
P2860
Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Response to rivastigmine or do ...... ncomitant Lewy body pathology.
@ast
Response to rivastigmine or do ...... ncomitant Lewy body pathology.
@en
Response to rivastigmine or do ...... ncomitant Lewy body pathology.
@nl
type
label
Response to rivastigmine or do ...... ncomitant Lewy body pathology.
@ast
Response to rivastigmine or do ...... ncomitant Lewy body pathology.
@en
Response to rivastigmine or do ...... ncomitant Lewy body pathology.
@nl
prefLabel
Response to rivastigmine or do ...... ncomitant Lewy body pathology.
@ast
Response to rivastigmine or do ...... ncomitant Lewy body pathology.
@en
Response to rivastigmine or do ...... ncomitant Lewy body pathology.
@nl
P2093
P356
P1476
Response to rivastigmine or do ...... ncomitant Lewy body pathology.
@en
P2093
Günter Rapatz
Howard Bergman
Jacques Touchon
Jennifer Nagel
Roger Bullock
Roger Lane
P356
10.1185/030079906X80279
P407
P577
2006-01-01T00:00:00Z